Ligand Pharmaceuticals Incorporated (LGND) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Ligand Pharmaceuticals Incorporated (LGND) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (56/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+269.1% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
How LGND Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | 44% | 15.3% | $124.5M | $48.9M | 3% |
| FY 2024 | $167.1M | 44% | -13.5% | -$4.0M | $95.2M | -2.2% |
| FY 2023 | $131.3M | 44% | 9.1% | $52.2M | $43.7M | 0.4% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring LGND)
- ✓Live walkthrough of LGND's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
LGND Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on LGND today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for LGND. Explore sector supply chains on /butterfly.
LGND Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Ligand Pharmaceuticals Incorporated (LGND)?
In FY 2025 (10-K), LGND converted $268.1M of revenue into a 44% gross margin, 15.3% operating margin, and $48.9M in free cash flow (18.2% FCF margin).